The FDA designates Johnson & Johnson’s

cadazolid an Orphan Drug for the treatment of

Clostridium difficile (C. diff) infection

in pediatric patients.

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

Cadazolid is a quinoxolidinone antibiotic being developed by Actelion.